Seminar “Biomarkers of neuroplasticity in congenital deafness treatment with cochlear implantation – is MMP-9 a one?”

The final seminar in the SAME-NeuroID project series will focus on the treatment of congenital deafness in children. Genetic and biochemical research may, in the future, enable the assessment of which pediatric patients are most likely to benefit from cochlear implantation.

On July 10 at 2:00 PM, in the Łukasiewicz – PORT lecture hall, Dr. hab. Monika Matusiak will present how identifying molecular and genetic biomarkers of neuroplasticity in children with congenital deafness treated with cochlear implantation can support a more personalized clinical approach and improve outcomes in auditory and language rehabilitation.

Dr. hab. Monika Matusiak is a physician and specialist in otorhinolaryngology, audiology, and phoniatrics. She works at the World Hearing Center of the Institute of Physiology and Pathology of Hearing in Kajetany, near Warsaw. She specializes in the diagnosis and treatment of various forms of hearing loss and deafness and conducts research on the molecular basis of neuroplasticity in the auditory system following cochlear implantation in congenital deafness.

After the lecture, the speaker will meet with young researchers at PORT and will be happy to answer their questions.

The seminar will be streamed live: https://www.b2match.com/e/same-match-treat/sessions/c2Vzc2lvbjoyMDIxMzA=
The recording will also be made available after the event at: https://same-neuroid.eu/video/